Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | LAP3 | P28838 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011135 | 0.80 | SRC (0.58) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL259733 | 0.80 | SRC (0.58) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL122230 | 0.80 | SRC (0.58) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL1009459 | 0.80 | SRC (0.58) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL1009702 | 0.79 | CYP1A2 (0.50) | HPGDMEN1KMT2ALMNA | |
| Water SCHEMBL7889250 | 0.78 | SRC (0.56) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL19348724 | 0.77 | CYP3A4 (0.61) | HPGDMEN1KMT2ALMNA | |
| SCHEMBL19348760 | 0.76 | SRC (0.54) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL29227303 | 0.76 | HPGD (0.55) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL28781038 | 0.76 | SRC (0.67) | SRCL3MBTL1TDP1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240297343-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS SODIUM ION BATTERY, NONAQUEOUS POTASSIUM ION BATTERY, METHOD FOR PRODUCING NONAQUEOUS SODIUM ION BATTERY, AND METHOD FOR PRODUCING NONAQUEOUS POTASSIUM ION BATTERY | CENTRAL GLASS CO., LTD. (JP) | 2024-09-05 | — | — | US | disclosed |
| EP-4362158-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION, NON-AQUEOUS SODIUM-ION BATTERY, NON-AQUEOUS POTASSIUM-ION BATTERY, METHOD FOR MANUFACTURING NON-AQUEOUS SODIUM-ION BATTERY, AND METHOD FOR MANUFACTURING NON-AQUEOUS POTASSIUM-ION BATTERY | Central Glass Co., Ltd. (JP) | 2024-05-01 | — | — | EP | disclosed |
| CN-117561628-A | Nonaqueous electrolyte, nonaqueous sodium ion battery, nonaqueous potassium ion battery, method for producing nonaqueous sodium ion battery, and method for producing nonaqueous potassium ion battery | 中央硝子株式会社 | 2024-02-13 | — | — | CN | disclosed |
| WO-2022270561-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION, NON-AQUEOUS SODIUM-ION BATTERY, NON-AQUEOUS POTASSIUM-ION BATTERY, METHOD FOR MANUFACTURING NON-AQUEOUS SODIUM-ION BATTERY, AND METHOD FOR MANUFACTURING NON-AQUEOUS POTASSIUM-ION BATTERY | セントラル硝子株式会社 | 2022-12-29 | — | — | WO | disclosed |
| EP-3222624-B1 | IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME | CENTRAL GLASS CO LTD (JP) | 2019-11-06 | — | — | EP | disclosed |
| US-10287165-B2 | Imidic acid compound having divalent anion and process for producing the same | CENTRAL GLASS CO., LTD. (JP) | 2019-05-14 | — | — | US | disclosed |
| EP-3222624-A1 | IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME | Central Glass Co., Ltd. (JP) | 2017-09-27 | — | — | EP | disclosed |
| US-20170267528-A1 | IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME | CENTRAL GLASS CO., LTD. (JP) | 2017-09-21 | — | — | US | disclosed |
| EP-1798792-B1 | NONAQUEOUS ELECTROLYTE SOLUTION, AND NONAQUEOUS ELECTROLYTE BATTERY HAVING SAME | BRIDGESTONE CORP (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20080153005-A1 | Non-Aqueous Electrolyte and Non-Aqueous Electrolyte Battery Comprising the Same | BRIDGESTONE CORPORATION (JP) | 2008-06-26 | — | — | US | disclosed |
| EP-1798792-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, AND NONAQUEOUS ELECTROLYTE BATTERY HAVING SAME | Bridgestone Corporation (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267528-A1 | IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME | CA2, CA6, CHRM1 | SRC 2676/4885L3MBTL1 3225/4885TDP1 4186/4885 |
| US-10287165-B2 | Imidic acid compound having divalent anion and process for producing the same | CA2, CA6, CHRM1 | SRC 2676/4885L3MBTL1 3225/4885TDP1 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.